発表論文 (Recent)

Update 5-JUN-2019

*Corresponding author(s)

2019

  1. Hiroshi Hamada, Yuta Goto, Jun Arakawa, Erisa Murayama, Yui Ogawa, Midori Konno, Takahiro Oyama, Masashi Asai, Akira Sato, Sei-ichi Tanuma, *Fumiaki Uchiumi. Characterization of the human E2F4 promoter region and its response to 12-O-tetradecanoylphorbol-13-acetate. The Journal of Biochemistry, in press. (IF=2.350, CiteScore=2.31 in 2017)
  2. Kazuaki Okada, Akira Sato, Akiko Hiramoto, Rena Isogawa, Yuji Kurosaki, *Kazutaka Higaki, Shin-Ichi Miyoshi, Kyung-Soo Chang, *Hye-Sook Kim. Pharmacokinetic analysis of new synthetic antimalarial N-251. Tropical Medicine and Health, in press. (SJR=0.563, CiteScore=1.130 in 2017)
  3. Yoko Ogino, Akira Sato, Fumiaki Uchiumi, Sei-ichi Tanuma. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells. Genomics, in press. doi: 10.1016/j.ygeno.2018.12.012. (IF=3.270 in 5-Year, IF=2.91 in 2017, CiteScore=2.97 in 2017)
  4. Yasunobu Asawa, Kiyotaka Katsuragi, Akira Sato, Atsushi Yoshimori, *Sei-ichi Tanuma, *Hiroyuki Nakamura. Structure-based drug design of novel carborane-containing nicotinamide phosphoribosyltransferase inhibitors. Bioorganic & Medicinal Chemistry, 27(13), 2832-2844, 2019. doi: 10.1016/j.bmc.2019.05.013. (IF=2.911 in 5-Year, IF=2.881 in 2017, CiteScore=2.90 in 2017)
  5. Mana InadaMika ShindoKyousuke Kobayashi, *Akira Sato, Yohei Yamamoto,  Yasuharu Akasaki, Koichi Ichimura, *Sei-ichi Tanuma. Anticancer effects of a non-narcotic opium alkaloid medicine papaverine in human glioblastoma cells. PLOS ONE, 14(5):e0216358. https://doi.org/10.1371/journal.pone.0216358 (IF=2.766, CiteScore=3.01 in 2017)
  6. Kenya Tamada, Shingo Nakajima, Natsumi Ogawa, Mana Inada, Hiroyuki Shibasaki, Akira Sato, Ryoko Takasawa, Atsushi Yoshimori, Yusuke Suzuki, Nobuo Watanabe, Takahiro Oyama, Hideaki Abe, Shigeaki, Inoue, Takehiko Abe, Takehiko Yokomizo, *Sei-ichi Tanuma. Papaverine identified as an inhibitor of high mobility group box 1/receptor for advanced glycation end-products interaction suppresses high mobility group box 1-mediated inflammatory responses. Biochemical and Biophysical Research Communications, 511(3), 665-670, 2019. doi: 10.1016/j.bbrc.2019.01.136 (IF=2.455 in 5-Year, IF=2.559 in 2017, CiteScore=2.62 in 2017)
  7. Hitoshi Tsugawa, Hideki Mori, Juntaro Matsuzaki, Akira Sato, Yoshimasa Saito, Masayo Imoto, Makoto Suematsu, *Hidekazu Suzuki. CAPZA1 determines the risk of gastric carcinogenesis by inhibiting Helicobacter pylori CagA-degraded autophagy. Autophagy, 15(2), 242-258, 2019. doi:10.1080/15548627.2018.1515530. (IF=11.100 in 2017, CiteScore=7.07 in 2017)

 

search previous next tag category expand menu location phone mail time cart zoom edit close